We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

1 hedge funds and large institutions have $2.35K invested in iTeos Therapeutics in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 135 closing their positions.

New
Increased
Maintained
Reduced
Closed

98.8% less ownership

Funds ownership: 98.8% → 0% (-99%)

99% less funds holding

Funds holding: 136 → 1 (-135)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $377M → $2.35K (-$377M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 135

Holders
1
Holders Change
-135
Holders Change %
-99.26%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
135
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
+$20

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$107M
2
BlackRock
BlackRock
New York
-$45.6M
3
TCM
Tang Capital Management
California
-$38.2M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$16.6M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$8.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
1
IFP Advisors
Florida
$2.35K +$20 +2 +0.9%
EC
2
EcoR1 Capital
California
– -$107M -10,688,978 Closed
BlackRock
3
BlackRock
New York
– -$45.6M -4,574,537 Closed
TCM
4
Tang Capital Management
California
– -$38.2M -3,826,692 Closed
Vanguard Group
5
Vanguard Group
Pennsylvania
– -$16.6M -1,664,161 Closed
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
– -$8.3M -832,761 Closed
BCM
7
Boxer Capital Management
California
– -$8.23M -825,000 Closed
Geode Capital Management
8
Geode Capital Management
Massachusetts
– -$7.02M -703,467 Closed
O
9
OrbiMed
New York
– -$6.98M -700,000 Closed
Marshall Wace
10
Marshall Wace
United Kingdom
– -$6.1M -611,649 Closed
Renaissance Technologies
11
Renaissance Technologies
New York
– -$6M -602,100 Closed
JP Morgan Chase
12
JP Morgan Chase
New York
– -$6M -601,363 Closed
NCM
13
Nantahala Capital Management
Connecticut
– -$5.95M -596,666 Closed
State Street
14
State Street
Massachusetts
– -$5.93M -594,555 Closed
DAM
15
DLD Asset Management
New York
– -$5.75M -576,655 Closed
NM
16
Newtyn Management
New York
– -$5.66M -567,416 Closed
LP
17
LMR Partners
United Kingdom
– -$5.48M -550,000 Closed
Alyeska Investment Group
18
Alyeska Investment Group
Illinois
– -$4.99M -500,000 Closed
AC
19
Almitas Capital
California
– -$4.86M -487,204 Closed
Millennium Management
20
Millennium Management
New York
– -$4.76M -477,189 Closed
Morgan Stanley
21
Morgan Stanley
New York
– -$4.28M -429,340 Closed
SCM
22
Stonepine Capital Management
Oregon
– -$3.09M -310,033 Closed
Bank of America
23
Bank of America
North Carolina
– -$3.08M -308,660 Closed
RC
24
Rangeley Capital
Connecticut
– -$3.01M -302,080 Closed
SPC
25
Silver Point Capital
Connecticut
– -$2.89M -290,000 Closed
1
2 3 4 5

ITOS Hedge Fund Activity: Q3 2025 in Review

1 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q3 2025, worth a combined $2.35K — down 100% from $377M a quarter earlier.

Sellers outnumbered buyers: 135 funds closed out of ITOS and 0 opened new positions — a net loss of 135 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was IFP Advisors, adding an estimated $20. The largest seller was EcoR1 Capital, exiting entirely with an estimated $107M sold.

  • 1 institutional investor held iTeos Therapeutics (ITOS) as of Q3 2025, down from 136 in Q2 2025.
  • Funds reported $2.35K of iTeos Therapeutics stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new iTeos Therapeutics positions in Q3 2025 and 135 closed out, a net change of -135 holders.
  • The largest iTeos Therapeutics buyer in Q3 2025 was IFP Advisors, an estimated $20 added.
  • The largest iTeos Therapeutics seller in Q3 2025 was EcoR1 Capital, an estimated $107M sold.

Based on aggregated 13F filings for Q3 2025.